Mecillinam - Reversion of Resistance and How to Test It

Mecillinam: A Possible Alternative Option for Non-Complicated Urinary Tract Infections Treatment Caused by Enterobacterales

N/a.

Antibiotic resistance in the invasive bacteria Escherichia coli

OBJECTIVES

The beta-lactamases with extended spectrum of activity (ESBL) are medically one of the most important group of enzymes. Another group of beta-lactamases representing of Enterobacteriaceae is group of the AmpC-type cephalosporinases. The presented study provides identification and determination of the spectrum of resistance against different and clinically used antimicrobial drugs in the clinical isolates of Escherichia coli.

METHODS

These isolates had origin in different departments of the L. Pasteur University Hospital in Košice. The goal was the detection of beta-lactamase production with extended-spectrum effect and testing of AmpC-type cephalosporinases by several phenotypic tests in clinical isolates. MALDI-TOF MS analysis was performed on a Microflex MALDI Biotyper. Samples were positively tested for ESBL with the use of the disc diffusion method. PCR were performed with a series of primers designed for the detection of Ambler class A, B and C beta-lactamase genes.

RESULTS

For all 485 isolates, we determined the production of ESBL, which we detected in 166 E. coli isolates, which represents a 34.2% prevalence of ESBL production. It is clear from the results that the prevalence of ESBL-producing E. coli out of the total number of E. coli investigated reached 34.2%. In the monitored period, we confirmed at least one resistance gene from 485 E. coli in 188 positive isolates.

CONCLUSIONS

We describe a complex ESBL epidemiology. The study revealed a high rate of ESBL-producing E. coli isolates; bla_TEM and bla_SHV enzymes dominated in ESBL-positive E. coli isolates in the L. Pasteur University Hospital in Košice.